[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
[2] |
肖梅仙,赵金波. 三阴性乳腺癌预后的临床相关因素[J]. 医学综述,2017, 23(2): 281-285.
|
[3] |
张丽,赵晓辉,佟仲生,等. 356例三阴性乳腺癌的临床特征及预后多因素分析[J]. 中国肿瘤临床,2010, 37(18): 1045-1049.
|
[4] |
刘玲玲,林芳,韩耀风,等. 不同分子分型乳腺癌术后复发转移风险及其时间分布规律[J]. 中国卫生统计,2017, 34(1): 7-10,14.
|
[5] |
瑞雪,刘志. 不同分子分型乳腺癌术后复发转移风险研究[J]. 中国继续医学教育,2018, 10(14): 89-92.
|
[6] |
Ribelles N, Perez-Villa L, Jerez JM, et al. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index[J]. Breast Cancer Res, 2013, 15(5): R98.
|
[7] |
Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer[J]. Ann Surg Oncol, 2018, 25(7): 1783-1785.
|
[8] |
Geurts YM, Witteveen A, Bretveld R, et al. Patterns and predictors of first and subsequent recurrence in women with early breast cancer[J]. Breast Cancer Res Treat, 2017, 165(3): 709-720.
|
[9] |
高娟,赵建国. 乳腺癌复发转移的相关因素分析[J]. 中华转移性肿瘤杂志,2019, 2(3): 60-61,64.
|
[10] |
李嘉琪,栾瑾微,张玉,等. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志,2019, 33(3): 244-249.
|
[11] |
van Maaren MC, de Munck L, de Bock GH, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study[J]. Lancet Oncol, 2016, 17(8): 1158-1170.
|
[12] |
Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer[J]. N Engl J Med, 2002, 347(16): 1227-1232.
|
[13] |
朱玮,张宏伟,陈君雪,等. 早期乳腺癌患者行乳房保留手术的疗效分析[J]. 中国临床医学,2012, 19(4): 416-419.
|
[14] |
Lagendijk M, van Maaren MC, Saadatmand S, et al. Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients[J]. Int J Cancer, 2018, 142(1): 165-175.
|
[15] |
岳雁鸿,王瑶,曾燕. 保乳术、改良根治术和改良根治术联合放疗治疗三阴性乳腺癌术后局部复发情况比较[J/CD]. 中华普外科手术学杂志(电子版), 2019, 13(2): 177-179.
|
[16] |
Yin W, Di G, Zhou L, et al. Time-varying pattern of recurrence risk for Chinese breast cancer patients[J]. Breast Cancer Res Treat, 2009, 114(3): 527-535.
|
[17] |
Manjili MH. Tumor dormancy and relapse: from a natural byproduct of evolution to a disease state[J]. Cancer Res, 2017, 77(10): 2564-2569.
|
[18] |
Demicheli R, Abbattista A, Miceli R, et al. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy[J]. Breast Cancer Res Treat, 1996, 41(2): 177-185.
|
[19] |
Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 376(22): 2147-2159.
|
[20] |
Schmid P, Cortés J, Dent R, et al. KEYNOTE-522: Phase Ⅲ study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)[J]. Ann Oncol, 2019, 30(Suppl 5): 853-854.
|